AstraZeneca ovarian cancer drug slows disease markedly in study

LONDON (Reuters) - AstraZeneca's ovarian cancer drug Lynparza slowed disease progression sharply in a closely watched clinical trial, boosting hopes for a product that belongs to a novel drug class called PARP inhibitors.